SAN FRANCISCO and SUZHOU, China, May 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other...
Hence then, the article about innovent announces oral presentation of full phase 2 clinical data for efdamrofusp alfa ibi302 first in class anti vegf complement bispecific fusion protein at arvo 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 )
Also on site :
- The Newest 'Fun Ship' in the World Just Picked a Surprising U.S. Homeport
- Ann-Margret Is About to Turn 85—Her Birthday Plans Might Surprise You (Exclusive)
- Most Australian teens admit the social media ban isn’t working as they try to sidestep age verification blocks with face masks and their parents’ IDs